Metabolic syndrome (MetS) is regarded as a risk factor for coronary artery disease (CAD). However, the influence of MetS on morbidity and mortality after drug-eluting stent (DES) implantation in Chinese patients with CAD remains unknown. We evaluated the impact of MetS on the clinical outcome of 1224 patients following DES implantation. After a mean follow-up of 35.4 months, patients with MetS had a significantly higher incidence of all-cause death and major adverse cardiovascular events (MACE) compared with patients without MetS (P < .001). Analyses of individual MetS components showed that dysglycemia at the time of DES implantation predicted increased all-cause mortality, while the presence of hypertension and dysglycemia predicted increased incidence of MACE.
Malik S., Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults . Circulation. 2004;110(10):1245-1250.
4.
Hong Y., Jin X., Mo J., et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med . 2007;262(1):113-122.
5.
Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr , Wilson PWImpact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219-1225.
6.
Jeppesen J., Hansen TW, Rasmussen S., Ibsen H., Torp-Pedersen C., Madsbad S.Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112-2119.
7.
Hu R., Ma CS, Nie SP, et al. Effect of metabolic syndrome on prognosis and clinical characteristics of revascularization in patients with coronary artery disease. Chin Med J (Engl). 2006; 119(22):1871-1876.
8.
Alberti KG, Zimmet P., Shaw J.The metabolic syndrome - a new worldwide definition. Lancet . 2005;366(9491):1059-1062.
9.
Hanley AJ, Wagenknecht LE, D’Agostino RB Jr , et al. Identification of subjects with insulin resistance and β-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes. 2003;52(11):2740-2747.
10.
Ascaso JF, Pardo S., Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care . 2003;26(12):3320-3325.
11.
Liao Y., Kwon S., Shaughnessy S., et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27(4):978-983.
12.
Cheal KL, Abbast F., Lamendola C., et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53(5): 1195-1200.
13.
Ikeda N., Nakajima R., Tsunoda T., et al. Insulin resistance and acute coronary syndrome in the young Japanese population have a strong association. Heart Vessels . 2007;22(3):165-169.
14.
Caccamo G., Bonura F., Bonura F., et al. Insulin resistance and acute coronary syndrome. Atherosclerosis.2010;211(2):672-675.
15.
Payne GA, Borbouse L., Kumar S., et al. Epicardial perivascular adipose-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway. Arterioscler Thromb Vasc Biol.2010 ;30(9):1711-1717.
16.
Otsuka F., Sugiyama S., Kojima S., et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48(6):1155-1162.
17.
Inoue T., Kotooka N., Morooka T., et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol. 2007; 100(4):569-574.
18.
Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-414.
19.
Levantesi, Macchia A., Marfisi R., et al, on behalf of the GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol.I. 2005;46(2):277-283.
20.
Kasai T., Miyauchi K., Kurata T., et al. Prognostic value of the metabolic syndrome for long-term outcomes in patients undergoing percutaneous coronary intervention. Circ J. 2006;70(12): 1531-1537.
21.
Feinberg MS, Schwartz R., Tanne D., et al. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol. 2007;199(5):667-672.
22.
Kasai T., Miyauchi K., Kajimoto K., et al. Relationship between the metabolic syndrome and the incidence of stroke after complete coronary revascularization over a 10-year follow-up period. Atherosclerosis.2009;207(1):195-199.
23.
Dohi T., Miyauchi K., Kasai T., et al. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J.2009;73(8):1454-1458.
24.
Hoffmann R. , Stellbrink E., Schröder J., et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol. 2007;100(()):1347-1352.
25.
Canibus P., Faloia E., Piva T., et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism. 2008;57(5):593-597.
26.
Bruno G., Merletti F., Biggeri A., et al. Casale Monferrato Study. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004;27(11):2689-2694.
27.
Yatskar L., Holper E., Bansilal S., et al. Long-term outcomes in non-diabetic patients with metabolic syndrome undergoing revascularization for multi-vessel coronary artery disease. Atherosclerosis. 2008;198(2):389-395.
28.
Sattar N., McConnachie A., Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371(9628): 1927-1935.
29.
Kim JS, Lee HC, Choi BK, et al. Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation. Diabetes Res Clin Pract.2010; 88(3):e38-e41.
30.
Alberti KG, Zimmet PZDefinition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7): 539-553.
31.
Balkau B., Charles MAComment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442-443.
32.
2001Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2002;285:2486-2497.
33.
Bloomgarden ZT2003American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care26:1297-1303.
34.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National heart, lung, and blood institute scientific statement . Circulation. 2005;112(17):2735-2752.
35.
Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) . J Hypertens. 2007;25(8):1105-1187.
36.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation.2009;120(16):1640-1645.
37.
Hansen TW, Thijs L., Li Y., et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension.2010;55(4): 1049-1057.
38.
Norhammar A. , Lagerqvist B., Saleh N.Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. EuroIntervention.2010 ;5(8):891-897.
39.
Jensen LO, Maeng M., Thayssen P., et al. Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol.2010;105(11):1513-1519.
40.
Kasai T., Miyauchi K., Kurata T., et al. Impact of metabolic syndrome among patients with and without diabetes mellitus on long-term outcomes after percutaneous coronary intervention . Hypertens Res. 2008;31(2):235-241.
